Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safimaltib First-in-Human Study in NHL and CLL
NCT03900598Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 1, open-label trial of JNJ-67856633 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 21 days and Adverse Events. Started Apr 2019; status: completed.
02
Drugs
JNJ-67856633
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03900598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900598.